TARGETING SPECIFIC LNCRNAS IN NOVEL COMBINED THERAPIES TO MODULATE THE TSP1-DEPENDENT IMMUNE MICROENVIRONMENT VULNERABILITIES IN ADVANCED THYROID CANCER

$1,723,552FY2025Defense Health AgencyDOD

Beth Israel Deaconess Medical Center, Inc.

Investigators

TARGETING SPECIFIC LNCRNAS IN NOVEL COMBINED THERAPIES TO MODULATE THE TSP1-DEPENDENT IMMUNE MICROENVIRONMENT VULNERABILITIES IN ADVANCED THYROID CANCER · GrantIndex